[Erectile dysfunction]
- PMID: 23830257
- DOI: 10.1016/j.purol.2013.01.010
[Erectile dysfunction]
Abstract
Introduction: Erectile dysfunction (ED) is the most commonly studied sexual disorder. ED is defined by a consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual activity.
Methods: Medical literature was reviewed and combined with expert opinion of the authors.
Results: A review of ED prevalence is less than 10% in men aged below 50, superior to 20% for men over 60. Age, cardiovascular diseases, diabetes, hypercholesterolemia, smoking, depression and psychiatric illness, psychological disorders, unfavorable socio-economic conditions are all risk factors for erectile dysfunction. Drug sexual side-effects must also be envisaged. Erectile dysfunction can be psychogenic, organic or a mix of both. The pathophysiological mechanisms are diverse and can implicate deterioration of the central or peripheral neural pathways, from the arterial supply to the penis, endothelial dysfunction, smooth muscle tone impairment, structural damage of the sinusoidal spaces of the erectile tissue, or even hormonal disorders. Psychological and sexological management can help some patients suffering from psychogenic erectile dysfunction, usually associated with pharmacological treatment. Phosphodiesterase type 5 inhibitors (PDE5i) on demand or daily are an efficient symptomatic treatment in two thirds of patients with all forms of erectile dysfunction. Diabetic patients, after radical prostatectomy and/or with severe cardiovascular diseases respond poorly to PDE5i. Intracavernous injections of PGE1 or vacuum pump provide second line treatment for most patients. Penile implants are third line treatment and when the indication is carefully established give excellent results.
Discussion: ED work-up and treatment are highly standardized. Therapeutic success rates are high.
Keywords: Dysfonction érectile; Effets secondaires sexuels; Epidemiology; Guidelines; Inhibiteurs de phosphodiestérase de type 5; Inhibitors; Management; PDE5; Pharmacological treatment; Physiopathologie; Physiopathology; Prise en charge; Recommandations; Sexual side-effects; Traitement médical; Épidémiologie.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies.Diabetes Metab. 2012 Feb;38(1):1-13. doi: 10.1016/j.diabet.2011.09.003. Epub 2011 Nov 4. Diabetes Metab. 2012. PMID: 22056307 Review.
-
[Erectile and Ejaculatory Dysfunction].Praxis (Bern 1994). 2015 Nov 25;104(24):1337-41. doi: 10.1024/1661-8157/a002194. Praxis (Bern 1994). 2015. PMID: 26602851 Review. German.
-
[Sex, erectile dysfunction, and the heart: a growing problem].Herz. 2003 Jun;28(4):284-90. doi: 10.1007/s00059-003-2478-8. Herz. 2003. PMID: 12825143 Review. German.
-
Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.BJU Int. 2013 Jul;112(2):E169-76. doi: 10.1111/j.1464-410X.2012.11561.x. Epub 2012 Dec 18. BJU Int. 2013. PMID: 23253640
-
Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates.BJU Int. 2012 Dec;110(11 Pt C):E954-7. doi: 10.1111/j.1464-410X.2012.11484.x. Epub 2012 Oct 19. BJU Int. 2012. PMID: 23078100
Cited by
-
Associations between Erectile Dysfunction and Vascular Parameters: A Systematic Review and Meta-Analysis.World J Mens Health. 2024 Oct;42(4):712-726. doi: 10.5534/wjmh.230192. Epub 2024 Jan 15. World J Mens Health. 2024. PMID: 38311372 Free PMC article.
-
Efficacy of L-arginine and Pycnogenol ® in the treatment of male erectile dysfunction: a systematic review and meta-analysis.Front Endocrinol (Lausanne). 2023 Oct 4;14:1211720. doi: 10.3389/fendo.2023.1211720. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37908749 Free PMC article.
-
Sexual Functions Following Cardiac Resynchronization Therapy: Evaluation of Male Patients and Their Partners.Cureus. 2023 Jun 8;15(6):e40163. doi: 10.7759/cureus.40163. eCollection 2023 Jun. Cureus. 2023. PMID: 37431349 Free PMC article.
-
[Prevalence and severity of erectile dysfunction in patients with type 2 diabetes in the Department of Urology at the University Hospital Center Hassan II, Fez, Morocco: a cross-sectional study of 96 cases].Pan Afr Med J. 2020 Oct 30;37:205. doi: 10.11604/pamj.2020.37.205.21774. eCollection 2020. Pan Afr Med J. 2020. PMID: 33598065 Free PMC article. French.
-
A Systematic Review on Rho-Kinase as a Potential Therapeutic Target for the Treatment of Erectile Dysfunction.Res Rep Urol. 2020 Jul 17;12:261-272. doi: 10.2147/RRU.S255743. eCollection 2020. Res Rep Urol. 2020. PMID: 32766173 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials